Upfront payments and deferred revenue

An upfront payment on a collaboration is recorded as cash and deferred revenue, a contract liability, until the related performance obligations are satisfied. If the license is distinct and transfers at signing, a large share of the upfront is recognized immediately. If the license is combined with research services, the upfront is recognized over the period of those services, frequently three to five years.

Deferred revenue on a biotech balance sheet is therefore a signal: it says the company has received cash it has not yet earned, which is good for runway and neutral for the income statement until the pattern of recognition runs its course. Auditors focus on the recognition pattern and the estimate of total costs when an input method is used, because changes in the estimate produce cumulative catch-up adjustments.

Boards should read deferred revenue together with the cash forecast. It is not a debt to be repaid, but it does represent work the company has committed to perform.